BGB-A445

• Description:

  BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC) . BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the research of cancer, such as colon adenocarcinoma[1][2].

• UNSPSC:

  12352203

• Target:

  NF-κB; Orexin Receptor (OX Receptor)

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling; NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• References & Citations:

  [1]Jiang B, et al. BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Front Med. 2023 Dec;17 (6) :1170-1185.|[2]Jiang B, et al. A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• CAS Number:

  [3033874-57-3]